Navigation Links
GeoVax to Present at the BIO CEO & Investor Conference 2009
Date:1/28/2009

ATLANTA, Jan. 28 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today announced that Robert McNally, Ph.D., Chief Executive Officer and President, will present a corporate update at the Eleventh Annual BIO CEO & Investor Conference 2009, held at the Waldorf-Astoria Hotel, in New York, on February 9-10, 2009.

The BIO CEO & Investor Conference is the preeminent gathering of cutting edge biotechnology companies, represented by senior executives, presenting their achievements to institutional investors, industry analysts and portfolio senior executives. Presenting companies were selected through a competitive screening process with a focus on their potential to deliver near-term clinical accomplishments in areas of unmet medical need. The expected attendance at the conference will include representatives from nearly 80 investment firms with a specific interest in life science companies.

Dr. McNally will present an overview of GeoVax's vaccine technology and will report the latest progress on the Company's Phase 2a preventative human vaccine trial and plans for upcoming therapeutic human vaccine trials. Dr. McNally also plans to meet one-on-one with current and prospective GeoVax investors, analysts, investment bankers and other potential Company partners.

"Having met significant milestones entering Phase 2a human trials with our highly promising HIV-1/AIDS vaccines and with our plans to launch our therapeutic human trials in the near future, the time has arrived for the Biotech sector and its respective investment audience to learn about our progress. We feel privileged to be among a select group of biotech companies showcasing our technologies to an elite group of interested investment
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GeoVax Labs, Inc. Second Quarter Financial Results and Operational Update
2. U.S. Government Awards $15 Million Grant to GeoVax Labs HIV/AIDS Vaccine Program
3. GeoVax Further Strengthens Management Team
4. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
5. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
6. GeoVax Presents Data at AIDS Vaccine 2008 Conference
7. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
8. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
9. Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007
10. Avicena Group to Present at Noble Financial Conference
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... WEST LAFAYETTE, Ind. A new research ... "nanomechanical" properties of tiny structures undergoing stress ... insights to improve designs for microelectronics and ... spectroscopy, reveals information about how heating and ... their mechanical properties. Researchers have discussed the ...
(Date:8/28/2014)... The ability for organizations to attract ... allow individuals to perform at the highest of levels, ... looking to compete in this post–recession era. The ... as the sector increasingly focuses on the importance of ... have real results on the organization's development and the ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Sterlitech is ... polymeric membranes to its stable of products . ... molecular weight cut-offs and include membrane filters with surface ... increase in customer demand for our membrane process testing ... variety of flat sheet membranes,” explains Sterlitech President Mark ...
Breaking Biology Technology:Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 2
... the First Therapies to Address the Underlying Cause ... Paradigm -, SOUTH PLAINFIELD, N.J., Aug. 20 ... Lancet show that the investigational oral drug,PTC124 demonstrates ... that treatment with PTC124 results in statistically significant,improvements ...
... Aug. 20 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq:,ONTY) (TSX: ... from The Nasdaq,Stock Market on August 14, 2008 ... for continued listing on The NASDAQ Global Market,because ... specifies, among,other things, that (i) the market value ...
... Aug. 20 Crystal Research Associates, LLC,announced ... Informational Overview(R),(EIO(R)) on Generex Biotechnology Corporation (Nasdaq: ... be found at http://www.crystalra.com ., ... is a,specialty pharmaceutical company that aims to ...
Cached Biology Technology:PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 2PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 3PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 4PTC124 Shows Promising Activity in Cystic Fibrosis; Phase 2 Proof-of-Concept Data Published in the Lancet 5Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 2Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market 3Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 2Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation 3
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have ... and enhance the process of re-engineering cells for biomedical ... network biology methods to aid stem cell engineering. Details ... are described in two back-to-back papers in the journal ... broad range of uses for all types of cell-based ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the ... America,s 27th Annual Mouse Molecular Genetics Conference from ... Grove, California. These awards are meant to ... scientists from underrepresented groups into the mainstream of ... participation of young scientists at the Genetics Society ...
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
Breaking Biology News(10 mins):New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... incite the body to attack its own nerve tissue ... viral and nerve proteins. The dual-receptor observation suggests a ... triggered in susceptible young adults afflicted with multiple sclerosis ... scientists Qingyong "John" Ji, Antoine Perchellet, and Joan M. ...
... LAFAYETTE, Ind. - Isolating a gene that allows a type ... researchers hope to use the finding to create plants that ... metal. The fern Pteris vittata can tolerate 100 to ... professor of botany and plant pathology, and David Salt, a ...
... at Chicago have discovered that an unexpected cellular response ... the formation of excess scar tissue in wound healing. ... Nature Cell Biology . When an organism ... wound site that rapidly produce extracellular matrix proteins such ...
Cached Biology News:Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 2Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 3Virus infection may trigger unusual immune cells to attack nerves in multiple sclerosis 4Fern's evolution gives arsenic tolerance that may clean toxic land 2Researchers discover mechanism that limits scar formation 2
... BIP-NC H-IPMIK-OH Lyophilized ... FROM LIGHT. HYGROSCOPIC. PACKAGED UNDER INERT GAS. ... Peptide, V5 (Cat. No. 196810) that serves ... Bax-mediated apoptosis (~200 μM). Purity: ≥97% ...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
... flexible, fully automated microplate strip washer for 96- ... automated microplate strip washing capability, the Columbus combines ... operation. , Features ... 8, 12 or 16 channels, crosswise aspiration, overflow ...
... Model 1575 immunowash microplate washer 100-240 V, ... have flat-, U-, or V-bottom wells. The ... and vertical needle positions to an accuracy ... aspiration, and overflow washing. It can store ...
Biology Products: